Investment highlights

Sosei Heptares is an international biopharmaceutical group focused on the discovery and early development of new medicines in areas of high unmet medical need.

We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurological, gastroenterology/immunology and inflammatory diseases

We leverage our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities in the discovery and design of our new drug candidates.


Why invest in us?

  • Our track record of successful approved medicines which underpin strong and stable royalty streams to support our research and development

  • Our dedicated scientists, clinicians and employees whose ideas and research are regularly published in the most prestigious academic journals globally

  • Our proprietary StaR® technology fuels our discovery efforts and has created multiple clinical candidates; furthermore, world-leading pharmaceutical companies have extensively sought to license the technology for their own programs

  • Our SBDD platform continually refills our pipeline with high-value drug candidates

  • Our diversified and deep in-house and partnered pipeline across multiple therapeutic areas including neurology, gastroenterology, immunology and inflammatory diseases

  • Our flexible business model combines in-house development, multiple existing and new partnerships and joint ventures

  • Our robust IP estate of over 60+ patent families, 320+ issued patents and 200+ patent applications

  • Our management team with over 150 years’ combined industry experience across the global pharma and biotech landscape